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Abstract 33 
Background: In utero exposure to obesity is consistently associated with increased risk of 34 
metabolic disease, obesity and cardiovascular dysfunction in later life despite the divergence 35 
of birth weight outcomes. The placenta plays a critical role in offspring development and 36 
long-term health, as it mediates the crosstalk between the maternal and fetal environments. 37 
However, its phenotypic and molecular modifications in the context of maternal obesity 38 
associated with fetal growth restriction remain poorly understood.  39 
Methods: Using a mouse model of maternal diet-induced obesity, we investigated changes in 40 
the placental transcriptome through RNA-seq and Ingenuity Pathway Analysis (IPA) at 41 
embryonic day (E) 19. The most differentially expressed genes (FDR < 0.05) were validated 42 
by qPCR in male and female placentae at E19. The expression of these targets and related 43 
genes was also determined by qPCR at E13 to examine whether the observed alterations had 44 
an earlier onset at mid-gestation. Structural analyses were performed using 45 
immunofluorescent staining against Ki-67 and CD31 to investigate phenotypic outcomes at 46 
both time points. 47 
Results: RNA-seq and IPA analyses revealed differential expression of transcripts and 48 
pathway interactions related to placental vascular development and tissue morphology in 49 
obese placentae at term, including downregulation of Muc15, Cnn1 and Acta2. Pdgfb, which 50 
is implicated in labyrinthine layer development, was downregulated in obese placentae at 51 
E13. This was consistent with the morphological evidence of reduced labyrinth zone size, as 52 
well as lower fetal weight at both time points irrespective of offspring sex. 53 
Conclusions: Maternal obesity results in abnormal placental labyrinth zone development and 54 
impaired vascularization, which may mediate the observed fetal growth restriction through 55 
reduced transfer of nutrients across the placenta.  56 
  57 
Introduction 58 
The prevalence of obesity has nearly tripled since 1975 [1]. As a consequence, the 59 
number of women who are classified as overweight or obese during pregnancy has risen 60 
substantially, estimated at 38.9 million in 2014 [2]. This is especially concerning as offspring 61 
born to obese mothers are more likely to have poor neonatal outcomes [3] and to develop 62 
obesity, insulin resistance, hypertension and dyslipidemia later in life [4]. Interestingly, 63 
maternal obesity leads to divergent birth weight outcomes; while it is often shown to increase 64 
the risk of macrosomia [5, 6], a higher incidence of low birth weight is also documented [6-65 
8]. Although both are similarly associated with metabolic disease in later life, distinct 66 
placental alterations seem to mediate these contrasting offspring phenotypes [9].  67 
Changes in placental function are thought to be pivotal in the development of 68 
pregnancy complications [10, 11] and could also be a key link between the maternal and 69 
intrauterine milieu and long-term health of the offspring [12, 13]. Alterations in placental 70 
function and structure in response to obesity and their underlying molecular mechanisms 71 
have been explored both in humans and in animal models [9, 14-17]. Yet, even though fetal 72 
growth restriction (FGR) is recognized as a placenta-related disorder [18], the impact of 73 
maternal obesity on the placental transcriptome in this context remains largely unknown. 74 
It has been shown that placentae from high fat diet-fed obese mouse dams exhibit 75 
altered expression of epigenetic machinery genes at term, which could alter the placental 76 
epigenome and lead to FGR [19]. High fat diet-induced obesity has also been found to alter 77 
the transcriptome of placenta progenitor cells at early stages of development and is associated 78 
with later changes in placental function resulting in FGR [17]. In our mouse model of 79 
maternal diet-induced obesity, in which dams are fed a hypercaloric Western-like diet, we 80 
have shown that maternal hyperinsulinemia is strongly associated with offspring insulin 81 
resistance and excess placental lipid deposition and hypoxia [20]. However, a clear 82 
understanding of the molecular mechanisms behind these findings is still lacking and 83 
warrants further investigation.  84 
It is recognized that the impact of stressors on placental function and offspring health 85 
is closely linked to the stage of tissue development, the type of insult and the sex of the 86 
conceptus [21]. Thus, the aim of this study was to identify global changes in the placental 87 
transcriptome and related pathways in response to maternal obesity near term at embryonic 88 
day (E) 19. Furthermore, we investigated whether the significant transcriptional alterations 89 
detected in obese placentae were manifested earlier, i.e. in mid-gestation (E13), and if these 90 
alterations translated into a structural phenotype in male and female placentae.  91 
 92 
Methods 93 
Animals and diets 94 
All experimental protocols were approved by the University of Cambridge Animal 95 
Welfare and Ethical Review Board and were carried under the Home Office Animals 96 
(Scientific Procedures) Act 1986. The model has been described in detail previously [20, 22]. 97 
Briefly, female C57BL/6J mice, proven breeders, were randomly assigned either a standard 98 
chow RM1 diet [7% simple sugars, 3% fat (wt/wt), 10.74 kJ/g] or an energy-rich highly 99 
palatable obesogenic diet [10% simple sugars, 20% animal lard (wt/wt), 28.43 kJ/g] 100 
supplemented with sweetened condensed milk [55% simple sugar, 8% fat (wt/wt); Nestle, 101 
Croydon, UK] and fortified with mineral and vitamin mix AIN93G. Both diets were fed ad 102 
libitum and purchased from Special Dietary Services (Witham, UK). Body composition was 103 
monitored (TD-NMR, Bruker Minispec) and females were set up to breed if body fat was 104 
between the thresholds of 10-12% or 35-40% for Control and Obese dams, respectively. 105 
After mating for the second time with RM1 fed males, dams were killed at either E13 or E19 106 
by rising CO2 concentration. Fetal and placental weights were recorded. Placentae for 107 
molecular analysis were immediately snap frozen on dry ice and stored at -80°C. For 108 
morphological assessment samples were fixed in 10% formalin for 48h, stored in 70% 109 
ethanol and then embedded in wax.  110 
The sex of the fetuses at E19 was determined by visual inspection of anogenital 111 
anatomy. At E13, DNA extracted from tail tips was used for PCR sexing as described by 112 
McFarlane et al. (2013), using the SX primer pair [23]. Amplicons were loaded on 2% 113 
agarose gels and submitted to electrophoresis together with a 1 Kb DNA ladder. Bands were 114 
visualized with SYBR™ Safe DNA gel stain (Thermo Fisher Scientific, Rochford, UK) 115 
under UV-illumination and the genomic sex of each sample was determined according to the 116 
number of bands and amplicon size. 117 
 118 
RNA extraction 119 
Placenta aliquots were homogenized in 700 uL Qiazol using TissueRuptor (Qiagen, 120 
Manchester, UK). Total RNA was isolated with miRNeasy Mini Kit (Qiagen) according to 121 
the manufacturer's instructions and including the optional step of DNA digestion with RNase-122 
Free DNAse Set (Qiagen). Extracted RNA was quantified by spectrophotometry (Nanodrop™ 123 
Thermo Fisher Scientific) and stored at -80 °C. 124 
 125 
RNA sequencing and Ingenuity® Pathway Analysis 126 
Total RNA was extracted from E19 male placentae (Control n = 2; Obese n = 3), as 127 
previously outlined. One µg of total RNA was depleted of ribosomal RNA and PolyA tails of 128 
coding RNAs were captured by treatment with Oligo-dT beads. Complementary DNA 129 
(cDNA) libraries were generated after an amplification step, according to the TruSeq 130 
Stranded Total RNA Sample Preparation Guide (Illumina, San Diego, CA, USA), and 131 
quantified using KAPA Library Quantification Kit. Multiplex single-read sequencing was 132 
performed using Illumina HiSeq 2500 (Illumina). Sequence reads were demultiplexed using 133 
the CASAVA pipeline (Illumina) and then aligned to the Mus Musculus genome (GRCm38) 134 
using TopHat version 2.0.11. Raw read counts and fragments per kilobase of transcript per 135 
million mapped reads (FPKM) were generated using Cufflinks version 2.2.1.  A quality check 136 
of mapped reads was executed using the R package CummeRbund. Databases were trimmed 137 
for exclusion of very low detection or undetectable genes. The resulting data were analyzed 138 
using edgeR by calculating the likelihood ratio, and by adjusting P-values via Benjamini and 139 
Hochberg’s method to control the false discovery rate. Ingenuity Pathway Analysis (IPA) 140 
was applied to identify biological pathways related to the genes that were differentially 141 
expressed between Control and Obese E19 male placentae. The placenta RNA sequencing 142 
(RNA-seq) data has been deposited in GEO database under the accession number 143 
GSE140013. 144 
 145 
cDNA synthesis and qPCR 146 
Total RNA was extracted from male and female placentae of Control and Obese dams 147 
at E13 (n = 10/group from separate litters) and E19 (n=9/group from separate litters). All 148 
samples used in the validations were different to those used in the RNA-seq and therefore 149 
represent biological replicates. Sample size was based on previous datasets/power 150 
calculations. cDNA was generated from 1 μg RNA using High Capacity cDNA Reverse 151 
Transcription Kit (Applied Biosystems, Foster City, CA, USA). Quantitative real time PCR 152 
(qPCR) was performed on QuantStudio 7 Flex Real-Time PCR System (Applied 153 
Biosystems), using 200 nM specific primers (Sigma-Aldrich, Gillingham, UK), 1× 154 
SYBR® Green JumpStart™ Taq ReadyMix (Sigma-Aldrich) and cDNA samples at a final 155 
dilution of 1:60. For primer sequences see Supplementary Table S1. NormFinder software 156 
was used to select the best combination of two out of four reference genes [24]. qPCR results 157 
were normalized to the geometric mean of the reference genes Gapdh and Sdha for E19 158 
placentae, and Gapdh and Pmm1 for E13 placentae, expression of which did not change 159 
between groups. Data was expressed in arbitrary units relative to Male Control average (2-160 
ΔΔCq). 161 
 162 
Structural analyses  163 
E13 and E19 formalin-fixed placentae from males and females were cut into 5µm 164 
sections. Three serial sections close to the midline of each placenta were selected for staining. 165 
Antigen retrieval was performed with pH9 Target Retrieval buffer [S2375 (Dako Agilent, 166 
Stockport, UK)] and non-specific binding sites were blocked with 3% goat serum. Sections 167 
were incubated overnight at 4oC with rabbit polyclonal primary antibodies against Ki67 168 
[1:200; ab15580 (Abcam, Cambridge, UK)] or CD31 [1:500; ab124432 (Abcam)].  169 
Primary antibody binding was visualized by incubation at room temperature for 1 170 
hour with a fluorescent-conjugated goat polyclonal anti-rabbit IgG [1:1000; A11008 171 
(Invitrogen, Warrington, UK)]. In negative control slides, placental sections were incubated 172 
in 1.5% goat serum in TBS-T instead of primary antibodies (Supplementary Figure S1). All 173 
sections were incubated with 1:2500 DAPI for 10 minutes at room temperature to stain 174 
nuclei. Autofluorescence was quenched by incubation with Vector TrueVIEW 175 
Autofluorescence Quenching Kit [SP8400 (Vector Laboratories, Peterborough, UK)].  176 
Placental sections were imaged on an AxioScan Slide Scanner (Zeiss, Cambridge, 177 
UK) and blindly analyzed using HALO analysis software (Indica Labs, Corrales, NM, USA). 178 
The DAPI channel image was used to define nuclear outlines using the CytoNuclear FL 179 
module. For the analysis of Ki67 staining (Supplementary Figure S2), nuclear outlines were 180 
transposed onto the 488nm channel image and the proportion of nuclei positive for Ki67 181 
across the whole section was recorded. Placental sections stained for the endothelial cell 182 
marker CD31 were used to investigate labyrinth zone (LZ) size and structure 183 
(Supplementary Figure S3). The border of the LZ was outlined manually at 40X 184 
magnification (depicted in yellow) and total area was recorded using HALO analysis 185 
software after canals were excluded. The boundary with the junctional zone was determined 186 
as the interface between the phenotypically distinct spongiotrophoblast of the junctional zone 187 
and the fetal capillaries of the LZ. The rest of the boundary was either at the edge of the 188 
tissue image or at the interface with the chorionic plate, which is structurally distinct from the 189 
LZ, characterized by smaller nuclei and the absence of CD31-positive endothelial cells. 190 
Indica Labs' Tissue Classifier module was used to differentiate between fetal blood vessels 191 
(lumen bound by CD31-positive endothelium) and other tissue of the LZ.  192 
 193 
Statistical analyses  194 
Benjamini-Hochberg multiple testing correction [25] was applied to the RNA-seq 195 
differential expression data and only genes with False Discovery Rate (FDR) < 0.05 were 196 
considered significantly different between the two experimental conditions. For qPCR 197 
validation of RNA-seq differentially expressed genes, comparisons were made between 198 
Control and Obese placentae of the same sex, by Student's t test.  199 
Anthropometric parameters and qPCR of selected targets were analyzed by two-way 200 
analysis of variance (ANOVA) followed by Tukey's multiple comparisons test to estimate the 201 
effects of maternal obesity and fetal sex at each time point.  202 
For the morphological analyses, the effects of gestational age (E13 or E19), offspring 203 
sex (male or female) and maternal diet (regular chow or obesogenic diet) on placental 204 
phenotype were investigated by three-way ANOVA, and backwards stepwise elimination was 205 
used to come to a minimal model.  Three-way ANOVA of the proportional area of the LZ 206 
that was fetal capillaries data revealed no significant effect of gestational age, maternal diet 207 
or fetal sex. However, there was a borderline significant interaction between maternal diet 208 
and fetal sex (P = 0.055). In order to identify if a maternal diet effect was only present in one 209 
sex, these data were separated and sex-specific two-way ANOVAs (gestational age / maternal 210 
diet) were performed.  211 
Only one sample from each litter was used for each analysis, except in the case of 212 
offspring and placental weights, in which each litter’s average was used as a single data 213 
point. Data are presented as mean ± standard error of the mean (SEM), and the threshold for 214 
significance was set at P< 0.05, unless stated otherwise. Statistical analyses were performed 215 
using R (R Core Team 2017) or Prism 6 (GraphPad Prism, La Jolla, CA, USA). 216 
 217 
Results 218 
Fetal and placental measurements 219 
Fetal and placental weights were reduced in response to obesity and female placentae 220 
were smaller than those of males at both stages of gestation. There was no significant 221 
difference in the ratio of fetal to placental weight, although there was a trend (P = 0.05) 222 
towards higher placental efficiency in females at E19 (Table 1). 223 
 224 
RNA-seq, Ingenuity® Pathway Analysis and qPCR at term placentae 225 
The RNA-seq at E19 detected a total of 350 transcripts differentially expressed in 226 
placentae of Obese compared to Control males considering a significance threshold of 227 
P < 0.05 (Figure 1A, Supplementary Table S2). However, only 9 genes remained 228 
significantly altered after correction for multiple testing (FDR < 0.05) (Figures 1A and 1B). 229 
Ingenuity® Pathway Analysis (IPA) was used with a less stringent threshold (P < 0.05) to 230 
identify global changes in pathways and biological functions promoted by maternal obesity. 231 
The most significant diseases and bio functions are shown in Figure 1C. 232 
Genes identified as significantly changed in response to obesity by RNA-seq (FDR < 233 
0.05) were validated in a larger number of samples, all from independent litters, by qPCR 234 
(Figure 2) and results were confirmed in 8 out of the 9 genes in E19 male placentae (i.e. 235 
Pi15, Gabrd, Sez6l, Nup210, Acta2, Rnf222, Muc15 and Cnn1). These genes were also 236 
examined in female placentae, however, only Pi15, Nup210, Acta2, Rnf222 and Muc15 were 237 
significantly modulated by obesity (Figure 2). 238 
 239 
Placental gene expression at different gestational ages 240 
All 9 genes found differentially expressed in obese male placentae at E19 were then 241 
investigated in E13 placentae (Figure 3A). Pi15, Nup210 and Sez6l were upregulated by 242 
maternal obesity in both sexes at mid-gestion. Gabrd mRNA levels, which were upregulated 243 
in Obese male placentae at E19, was downregulated by maternal obesity at E13. Muc15, 244 
Nup210 and Acta2 expression was higher in females compared to males at E13. Rnf222 and 245 
Cnn1 were not differentially expressed in either sex at E13, however, their transcript levels 246 
were very low compared to E19. 247 
Since genes involved in spiral artery remodeling (Muc15 and Cnn1) and labyrinthine 248 
pericytes (Acta2) that were found to be dysregulated in obese placentae at E19 were not 249 
affected at E13, we additionally measured the expression of candidate genes recognized as 250 
relevant for these processes at mid-gestation. Both Hand1 and Pdgfb were downregulated by 251 
maternal obesity in both sexes, but no differences were observed in Prl2c2 (Figure 3B). 252 
 253 
Immunofluorescent staining of placental morphology 254 
Phenotypic analyses were also conducted by immunofluorescent staining of targets 255 
within pathways identified by IPA. The marker Ki67 was used to investigate cellular growth 256 
and proliferation. Cellular movement, assembly and organization was assessed through 257 
analyses of LZ size and fetal vasculature structure, using CD31 as a marker of fetal 258 
endothelial cells.  259 
E19 placentae had fewer cells (P < 0.05, Figures 4A-C) and a lower proportion of 260 
proliferating cells across the whole placenta (P < 0.01, Figures 4D-H) compared to E13. 261 
These parameters were not affected by offspring sex or maternal diet. 262 
The size of the LZ was significantly reduced in placentae from obese dams (P < 0.01, 263 
Figures4I-M). There was a significant increase in LZ size from mid-gestation to term (P < 264 
0.01, Figure 4I). Labyrinthine vascular organization was analyzed by the proportion of the 265 
total LZ area that was fetal blood vessels. A reduced model considering males and females 266 
separately by two-way ANOVA (gestational age / maternal condition) detected a reduction in 267 
area bound by fetal capillaries within the LZ in female placentae of obese dams (P < 0.05, 268 
Figures 4N-P). Representative images of male placentae are shown in Supplementary 269 
Figure S4.  270 
 271 
Discussion 272 
The RNA-seq analysis revealed a total of 350 transcripts differentially expressed in 273 
Obese male placentae at term. Among the top downregulated transcripts, Muc15, Cnn1 and 274 
Acta2 were of particular significance as these genes are required for appropriate development 275 
of placental vasculature and related to key pathways identified by IPA such as cellular 276 
movement, assembly and organization. Previous studies have shown that Muc15 suppresses 277 
the migration/invasion of trophoblast like-cells in vitro, a process implicated in blood vessel 278 
remodeling in the maternal–fetal interface [26]. Cnn1 is largely expressed by smooth muscle 279 
cells [27] which line the uterine blood vessels and are lost in the normal remodeling of 280 
maternal spiral arteries during placental development [28]. Acta2 is a marker of pericytes 281 
which surround fetal endothelial cells during blood vessel development in the mouse LZ [29].  282 
These data together suggest that exposure to maternal obesity affects the remodeling 283 
of maternal spiral arteries and the development of fetal blood vessels within the LZ, both of 284 
which are crucial for adequate nutrient and oxygen transfer across the placenta [28] and 285 
possibly linked to the uteroplacental hemodynamic alterations present in pre-eclampsia and 286 
intrauterine growth restriction [30-32]. Obese women are two to three times more likely to 287 
develop pre-eclampsia [33] and hypertensive obstetric complications are  generally associated 288 
with small-for-gestational age neonates [34]. Here we see significant growth restriction in the 289 
fetus which may result from poor utero-placental perfusion in addition to placental hypoxia 290 
previously suggested in this model [20].  291 
Furthermore, the RNA-seq analysis identified several genes that have not been 292 
functionally described in placental tissue thus far, but are conserved in humans and rodents. 293 
Pi15 encodes a peptidase inhibitor that may regulate extracellular matrix modifications [35] 294 
and has been implicated in vascular defects in rat aorta [36], though its role in placental 295 
vascularization is unknown. Gabrd gene encodes the delta subunit of gamma-aminobutyric 296 
acid type A receptor (GABAA). GABAA activation impacts stromal cell proliferation and 297 
apoptosis during decidualization [37] and increased expression of its pi subunit (GABRP) has 298 
been detected in preeclamptic placentae [38]. NUP210 is a major component of the nuclear 299 
pore complex and is required for regulation of gene expression during differentiation and cell 300 
fate determination, as demonstrated in myoblasts and embryonic stem cells [39]. Although 301 
the function of SEZ6L is not well understood, it has been shown both in mice and in vitro 302 
that this protein is almost exclusively processed by β-site APP cleaving enzyme (BACE) 303 
[40]; BACE1 and BACE2 are abundantly expressed in human placentae and are up-regulated 304 
in pregnancies complicated with preeclampsia [41]. Lastly, Rnf222 is also a protein-coding 305 
gene, however no functional description has been found. 306 
Although information on these genes in placentae is currently limited, it must be 307 
noted that a large number of placental genes and related phenotypes remain uncharacterized. 308 
Recent efforts to systematically identify the genes required for normal embryogenesis are still 309 
unravelling many previously underappreciated placental defects [42]. Thus, our findings 310 
might represent novel targets that could be implicated in the pathophysiology of maternal 311 
obesity and associated adverse outcomes in the offspring. Moreover, additional genes might 312 
have been identified if a larger sample size was used in the RNA-seq analysis.   313 
When comparing both time points, most transcripts exhibited a different expression 314 
pattern, including Muc15, Cnn1 and Acta2 which were not affected by obesity at E13. This 315 
could be due to low functional relevance of these transcripts at mid-pregnancy rather than 316 
absence of alterations in related cellular processes, as illustrated by low Cnn1 mRNA levels 317 
in our analysis at E13 compared to E19 (data not shown). In fact, the mouse placenta 318 
undergoes a transcriptome transition from the “development phase” of organogenesis to the 319 
“mature phase” at mid-pregnancy [43].  320 
Thus, we next used the IPA data to identify genes which were previously shown to be 321 
both highly expressed at mid-pregnancy and pivotal to spiral artery remodeling and formation 322 
of fetal blood vessels in the LZ. Hand1, which is required for trophoblast giant cell (TGC) 323 
differentiation [44], was downregulated in placentae of obese dams. However, maternal 324 
obesity had no effect on the expression of Prl2c2, a marker of TGC that line maternal blood 325 
canal spaces and spiral arteries in the definitive placenta [45]. Considering the complexity of 326 
spiral artery remodeling and the limited number of transcripts that were analyzed here, it 327 
remains to be established whether the alterations occur only later in development or if other 328 
mechanisms are involved. 329 
On the other hand, the growth factor Pdgfb was downregulated in response to obesity 330 
at E13 and could be a relevant link to other molecular and phenotypic observations in our 331 
model. It has been shown that Pdgfb-deficient placentae exhibit defective labyrinthine 332 
development, with alterations in fetal blood vessel structure and reduced numbers of 333 
pericytes from mid-pregnancy until term, leading to growth restriction in PDGFB -/- embryos 334 
[29]. Here, lower expression of the pericyte marker Acta2 was detected by RNA-seq and 335 
confirmed by qPCR in obese placentae at E19. In addition, defects in LZ morphology and 336 
FGR were observed in response to maternal obesity at E13 and persisted until E19.  337 
As shown by our immunofluorescence staining, male and female placentae from 338 
Obese dams exhibited reduced LZ area, which is the primary site of gas, nutrient and waste 339 
exchange between the maternal and fetal circulations in the mouse [28], and a decrease in the 340 
proportion of fetal blood vessels within the LZ was also evident in females. This is further 341 
corroborated by recent evidence of lower vascularity in placentae of high fat diet-fed dams 342 
both at mid-pregnancy and near term, which was associated with placental transcriptome 343 
alterations in early stages of development and FGR [17]. In addition, it has been suggested 344 
that defects in placental villi vasculature seen in obese human pregnancies could be partly 345 
due to obesity-associated tissue hypoxia [46], which is also consistent with our model [20]. 346 
Next, we used IPA to investigate the mechanism behind this reduction in LZ area. 347 
Cellular growth and proliferation were pointed out as the main molecular and cellular 348 
functions affected by obesity. Surprisingly, however, maternal obesity had no effect on the 349 
number of Ki67-positive cells in the placenta. Abnormalities in placental size are often 350 
associated with disruption of cellular growth and/or apoptosis [47-49]. Thus, it is possible 351 
that other mechanisms such as cell death could explain our results, although limitations to our 352 
analysis, which was not zone-specific, cannot be discounted. In this regard, it has been shown 353 
in a mouse model of high fat diet-induced obesity through phosphohistone H3 staining that 354 
the proliferating cells in placenta are mostly restricted to the labyrinthine layer and appear 355 
reduced in response to obesity within this region [50]. 356 
Despite these morphological disturbances, changes in tissue structure that are 357 
expected to occur from mid-pregnancy until term seemed preserved in obese placentae. The 358 
LZ is well-reported to expand as pregnancy progresses, so that the transport capacity of the 359 
placenta can meet the nutrient demands of the growing fetus [50-52]. Accordingly, we found 360 
that labyrinth area increased between E13 and E19, irrespective of maternal diet. 361 
We also observed significant differences in placentae which are specific to fetal sex. 362 
Female placentae were smaller than male counterparts at all time points and maternal 363 
conditions, which is consistent with observations from both human cohorts [53] and studies 364 
in mice [19, 54]. Moreover, we found sex differences in a subset of genes, with females 365 
exhibiting slightly increased expression. Similarly, global transcriptomic analysis in normal 366 
full-term human placentae revealed higher overall mRNA levels in females compared to 367 
males [55]. Sexual dimorphism in the context of developmental programming is increasingly 368 
commonly reported [56]. How these relate to sex-specific responses of the placenta to a 369 
suboptimal environment remain to be determined. 370 
Overall, we have shown through genome-wide analysis that maternal obesity induces 371 
a dysregulation of transcripts and pathway interactions related to placental vasculature and 372 
structure. Fetal growth restriction, as well as changes in placental morphology and a gene 373 
expression signature associated with impaired labyrinthine development, were detectable at 374 
mid-pregnancy, suggesting an enduring negative effect of maternal obesity over these 375 
processes. The LZ is the exchange region of the murine placenta and reductions in its size 376 
and vasculature may impair the transport of nutrients from the maternal circulation to the 377 
developing fetus, thus restricting its growth. Disruption of placental structure could thus 378 
represent an important factor contributing to the development of FGR in pregnancies 379 
complicated by maternal obesity. Moreover, novel targets were revealed by our RNA-seq 380 
analysis. Characterizing their functional roles in the placenta will help us better understand 381 
the processes mediating the effects of maternal obesity on offspring outcomes and potentially 382 
inform suitable interventions. 383 
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  560 
Figure Legends 561 
Figure 1. RNA-seq identification of differentially expressed genes between Control (C, n=2) 562 
and Obese (O, n=3) male mouse placentae at E19. (A) Volcano plot representing all detected 563 
transcripts, distributed according to -log10 P-value in the y-axis and log2 Fold Change in the 564 
x-axis, with downregulated genes shifted to the left (P< 0.05 in blue) and upregulated genes 565 
shifted to the right (P< 0.05 in red). Significantly altered genes after correction for multiple 566 
testing (FDR < 0.05) are depicted with a pink diamond; (B) Heatmap representation of genes 567 
significantly regulated by maternal obesity using a cutoff FDR < 0.05, with scaled Z-score 568 
color key of normalized counts showing expression levels ranging from blue (lower) to red 569 
(higher). Genes are sorted from lowest to highest log2 Fold Change value; (C) Top Diseases 570 
and Bio Functions from Ingenuity® Pathway Analysis (IPA) of the RNA-seq data with a 571 
threshold of P< 0.05, showing the most significant molecular and cellular functions 572 
dysregulated in the placenta by maternal obesity, sorted by P-value.  573 
 574 
Figure 2. Validation of RNA-seq data by qPCR in E19 male and female placentae. qPCR 575 
results were normalized to the reference genes Gapdh and Sdha and are expressed as mean ± 576 
SEM in arbitrary units relative to Male Controls. * P< 0.05, determined by Student's t test 577 
comparing qPCR data of same sex Control vs Obese, n = 9/group. 578 
 579 
Figure 3. qPCR expression in E13 male and female placentae. (A) Validated RNA-seq 580 
genes; (B) Hand1, required for trophoblast giant cell (TGC) differentiation; Prl2c2, a marker 581 
of spiral artery-associated TGC and canal-associated TGC; Pdgfb, a growth factor that 582 
regulates placental labyrinthine layer development. qPCR data were normalized to the 583 
reference genes Gapdh and Pmm1. Results are shown as mean ± SEM in arbitrary units 584 
relative to Male Control average expression. * denotes Maternal Obesity effect (P< 0.05) and 585 
# denotes sex difference (P< 0.05), according to two-way ANOVA, n = 10/group. ª Rnf222 586 
and Cnn1 expression levels were low at E13 placentae, with average Cq values above 31 and 587 
29, respectively. 588 
 589 
Figure 4. Immunofluorescent staining of targets related to the top three Molecular and 590 
Cellular Functions shown in IPA. All analyses were conducted in both male and female 591 
placentae of mothers fed either regular chow (C, Control group) or obesogenic diet (Ob, 592 
Obese group), at E13 and E19. (A – C) The total number of cells in the placenta decreased 593 
between E13 (n = 20) and E19 (n = 19); (D – H) The proportion of Ki67-positive cells across 594 
the whole placenta decreased between E13 (n = 20) and E19 (n = 19); (I – M) The size of the 595 
labyrinth zone increased between E13 and E19, and was reduced in response to maternal 596 
obesity (C n = 10, Ob n = 9, at each time point); (N – P) The proportion of fetal capillaries 597 
within the labyrinth zone was decreased by maternal obesogenic diet in females (C n = 10, 598 
Ob n = 9). (A, D, I, N) Results are shown as mean ± SEM. Gestational age differences are 599 
denoted by *(P< 0.05), **(P< 0.001) or ***(P< 0.0001), and Maternal Obesity effect is 600 
indicated by #(P< 0.001), according to three-way ANOVA. § denotes Maternal Obesity 601 
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Table 1. Fetal and Placental weights at E13 and E19 
 
Control Obese P-value 
 





Fetal weight (g) 0.17 ± 0.01 0.16 ± 0.00 0.15 ± 0.01 0.14 ± 0.01 0.003 0.187 
Placental weight (mg) 94.0 ± 2.2 88.9 ± 3.5 89.7 ± 2.1 78.7 ± 2.9 0.015 0.008 
Fetal: Placental ratio 1.84 ± 0.06 1.85 ± 0.06 1.66 ± 0.08 1.76 ± 0.08 0.079 0.452 
E19 
Fetal weight (g) 1.23 ± 0.03 1.17 ± 0.03 1.02 ± 0.03 1.03 ± 0.02 < 0.0001 0.339 
Placental weight (mg) 93.8 ± 5.1 81.7 ± 5.3 82.8 ± 1.9 73.1 ± 2.7 0.039 0.021 
Fetal: Placental ratio 13.45 ± 0.76 14.77 ± 0.92 12.38 ± 0.37 14.28 ± 0.78 0.331 0.051 
Values are mean ± SEM. P-values < 0.05 indicated in bold show significant effect of maternal obesity and sex 
differences in the studied parameters according to two-way ANOVA followed by Tukey's multiple comparisons 
test, using each litter’s average as a single data (Control Male n = 6 and 9, Control Female n = 6 and 9, Obese 
Male n = 7 and 7, Obese Female n = 7 and 6, respectively at E13 and E19). 
